Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 1240 • 2016 ACR/ARHP Annual Meeting
A Minority of Patients Utilize Most of Healthcare Resources in Rheumatoid Arthritis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, and Axial Spondyloarthritis
Nina Mars¹, Anne M Kerola², Markku J Kauppi^3,4, Outi Elonheimo^5,6, Santeri Huvinen^5,6 and Tuulikki Sokka-Isler^7,8, ¹University of Helsinki, Helsinki, Finland, ²Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ³School of Medicine, University of Tampere, Tampere, Finland, ⁴Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁵Network of Academic Health Centres, Department of Medicine, University of Helsinki, Helsinki, Finland, ⁶FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁸RAID working group for EULAR, Zurich, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) is associated with high healthcare costs, but little is known about how the costs compare to other chronic rheumatic diseases. We…
Abstract Number: 387 • 2016 ACR/ARHP Annual Meeting
Rituximab Should be Considered in Rheumatoid Factor Negative Poly-Articular Juvenile Idiopathic Arthritis
Sunil Sampath^1,2, Liza J. McCann³, Michael W. Beresford^3,4, Eileen Baildam³, Jamie C Sergeant^1,5, Wendy Thomson², Helen Foster⁶, Sharon Douglas², Taunton Southwood⁷, Kimme L. Hyrich¹ and Biologics for Children with Rheumatic Diseases (BCRD) study Group¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ³Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁵NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁶Paediatric Rheumatology, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, ⁷School of Immunity and Infection,Institute of Clinical Sciences,University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Selective peripheral B-cell depletion by rituximab (RTX) is a relatively recent advance in rheumatic diseases. RTX is an approved treatment in RA. Although very…
Abstract Number: 1289 • 2016 ACR/ARHP Annual Meeting
Comparison of Clinical Parameters and PET/MRI in Juvenile Idiopathic Arthritis
Kathleen Jo Corbin¹, Emily von Scheven¹, Youngho Seo², Spencer Behr² and John MacKenzie³, ¹Division of Rheumatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, ²Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, ³Section of Pediatric Radiology, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA
Background/Purpose: Positron emission tomography (PET) can be used to identify inflammation using 18F-fluorodeoxyglucose (18F-FDG). 18F-FDG uptake correlates with clinical and laboratory markers of disease activity…
Abstract Number: 388 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Two to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis
Hermine I. Brunner¹, Nicolino Ruperto², Anasuya Hazra³, Ronnie Wang⁴, Charles Mebus⁴, Christine Alvey⁴, Manisha Lamba⁴, Sriram Krishnaswami⁴, Thomas C Stock³, Umberto Conte⁵, Min Wang⁵, Nikolay Tzaribachev⁶, Ivan Foeldvari⁷, Gerd Horneff⁸, Daniel Kingsbury⁹, Elena Koskova¹⁰, Elzbieta Smolewska¹¹, Richard K Vehe¹², Zbigniew Zuber¹³, Daniel J Lovell¹ and Alberto Martini², ¹Pediatric Rheumatology Collaborative Study Group, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Istituto Giannina Gaslini, Genoa, Italy, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Pediatric Rheumatology Research Institute, Bad Bramstedt, Bad Bramstedt, Germany, ⁷Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ⁸Asklepios Klinik, Sankt Augustin, Germany, ⁹Randall Children's Hospital, Portland, OR, ¹⁰National Institute of Rheumatic Diseases, Piestany, Piestany, Slovakia, ¹¹Department of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Lodz, Poland, ¹²University of Minnesota Masonic Children’s Hospital, Minneapolis, MN, ¹³St Louis Children’s Hospital ODS Rheumatology and Neurology, Krakow, Poland
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor that is being investigated for juvenile idiopathic arthritis (JIA). Here, we report the pharmacokinetics (PK), safety, and…
Abstract Number: 1517 • 2016 ACR/ARHP Annual Meeting
Does Inflammatory Arthritis Really Improve during Pregnancy? a Systematic Review and Meta-Analysis
Hannah Jethwa¹, Suzanne Lam², Colette Smith³ and Ian Giles⁴, ¹General Medicine, Wexham Park Hospital, London, United Kingdom, ²Croyden University Hospital, London, United Kingdom, ³Statistics, Royal Free Hospital Foundation Trust, London, United Kingdom, ⁴Centre for Rheumatology, University College London, Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Disease activity is considered to improve in approximately 75% of patients with rheumatoid arthritis (RA) during pregnancy. This figure, however, is derived from…
Abstract Number: 392 • 2016 ACR/ARHP Annual Meeting
Safety and Clinical Response of Weekly Adalimumab in the Treatment of Juvenile Idiopathic Arthritis, Pediatric Chronic Uveitis and Other Childhood Rheumatic Diseases
Colleen K. Correll¹, Danielle R. Bullock¹, Rachel Cafferty¹ and Richard K Vehe², ¹Pediatrics, University of Minnesota, Minneapolis, MN, ²University of Minnesota Masonic Children’s Hospital, Minneapolis, MN
Background/Purpose: Every other week adalimumab is used to treat juvenile idiopathic arthritis (JIA) and other pediatric rheumatic diseases. It is common for pediatric rheumatologists to…
Abstract Number: 2038 • 2016 ACR/ARHP Annual Meeting
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Improvement on Quality Measures for Children with Juvenile Idiopathic Arthritis
C. April Bingham¹, Jesse Pratt², Cagri Yildirim-Toruner³, Ronald Laxer⁴, Beth Gottlieb⁵, Jennifer E. Weiss⁶, Tzielan Lee⁷, Sheetal S. Vora⁸, Jon M. Burnham⁹, Julia Harris¹⁰, Judyann C. Olson¹¹, Murray Passo¹², Michelle Batthish¹³, Michael Shishov¹⁴, Kerry Ferraro¹⁵, Deborah M. Levy¹⁶, Christine O'Brien¹⁷, Kristi Whitney-Mahoney¹⁷, Nancy Griffin¹⁸, Anne Paul¹⁹ and Esi Morgan²⁰, ¹Penn State Health Children's Hospital, Hershey, PA, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁴Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Pediatrics, Cohen Children's Medical Center, Lake Success, NY, ⁶Hackensack Univ Med Ctr, Hackensack, NJ, ⁷Pediatric Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁸Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁹Pediatric Rheumatology, Children's Hospital Philadelphia, Philadelphia, PA, ¹⁰Children's Mercy Kansas City, Kansas City, MO, ¹¹Ped/MACC Fund Research Ctr, Medical College of Wisconsin, Milwaukee, WI, ¹²Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ¹³Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ¹⁴Pediatric Rheumatology, Phoenix Children's Hospital, Phoenix, AZ, ¹⁵Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ¹⁶Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁷The Hospital for Sick Children, Toronto, ON, Canada, ¹⁸James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁹Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁰Pediatric Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a growing multi-center network organized on a learning health system model designed to improve outcomes…
Abstract Number: 395 • 2016 ACR/ARHP Annual Meeting
The Influence of Early Achievement of “Clinically Inactive Disease” or “Minimal Disease Activity” on Long-Term Disability Outcomes in JIA
Stephanie J.W.Shoop^1,2, Suzanne M.M. Verstappen³, Janet E. McDonagh⁴, Wendy Thomson^5,6, Kimme L. Hyrich^3,7 and CAPS, ¹Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ²The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁷Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Different definitions of clinically inactive disease (CID) for JIA have recently been shown to identify different groups of children. It is unclear whether long-term…
Abstract Number: 2039 • 2016 ACR/ARHP Annual Meeting
Assessing Barriers to Uveitis Screening in Patients with JIA: A Qualitative Study
Laura Ballenger¹, Kyla Driest² and Stacy P. Ardoin³, ¹Nationwide Children's Hospital, Columbus, OH, ²Rheumatology, Nationwide Children's Hospital, Columbus, OH, ³Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH
Background/Purpose: Uveitis is a major complication in patients with juvenile idiopathic arthritis (JIA) can be completely asymptomatic until vision loss develops. In order to prevent ocular…
Abstract Number: 398 • 2016 ACR/ARHP Annual Meeting
Predictors of Clinical Remission with Etanercept in Pediatric Patients with Extended Oligoarticular, Enthesitis-Related Arthritis and Psoriatic Arthritis: Findings from the Clipper Study
Nicolino Ruperto¹, Alessandro Consolaro², Gerd Horneff¹, Rubén Burgos-Vargas¹, Tamas Constantin¹, Ivan Foeldvari¹, Jelena Vojinovic¹, Joke Dehoorne¹, Violeta Vladislava Panaviene¹, Gordana Susic¹, Valda Stanevicha¹, Katarzyna Kobusinska¹, Zbigniew Zuber³, Richard Mouy¹, Ingrida Rumba-Rozenfelde¹, Pavla Dolezalová¹, Chantal Job-deslandre⁴, Nico M Wulffraat¹, Ronald Pedersen⁵, Jack F Bukowski⁶, Tina Hinnershitz⁷, Bonnie Vlahos⁸ and Alberto Martini⁹, ¹Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ²Istituto Giannina Gaslini, Genoa, Italy, ³St Louis Children’s Hospital ODS Rheumatology and Neurology, Krakow, Poland, ⁴Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ⁵Department of Biostatistics, Pfizer, Collegeville, PA, ⁶Clinical Affairs, Pfizer, Collegeville, PA, ⁷Specialty Care MDG, Pfizer, Collegeville, PA, ⁸GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ⁹PRINTO-IRCCS, Genoa, Italy
Background/Purpose: Etanercept (ETN) is approved in the EU for the treatment of children with juvenile idiopathic arthritis (JIA) categories of polyarticular, extended oligoarticular (eoJIA), enthesitis-related…
Abstract Number: 2408 • 2016 ACR/ARHP Annual Meeting
Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88
Keith A. Sikora¹, Joshua R. Bennett¹, Zuoming Deng², Wanxia Li Tsai³, April Brundidge³, Fatemeh Navid³, Gerlinde Layh-Schmitt³, Eric Hanson³, Massimo G. Gadina⁴, Louis M. Staudt⁵, Thomas A. Griffin⁶ and Robert A. Colbert³, ¹Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Biodata Mining & Discovery, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Translational Immunology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵National Cancer Institute, National Institutes of Health, Bethesda, MD, ⁶Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC
Background/Purpose: Myeloid differentiation primary response 88 (MyD88) is a critical adaptor protein that connects Toll-like and IL-1 receptor signaling to activation of NF-κB. Germline loss-of-function…
Abstract Number: 405 • 2016 ACR/ARHP Annual Meeting
Patterns of Medication Use in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis & Rheumatology Research Alliance Registry
Sarah Ringold¹, Yukiko Kimura², Laura E. Schanberg³, Marc D. Natter⁴, Fenglong Xie⁵, Norman Ilowite⁶, Jason Jones⁷, Kelly Mieszkalski⁸, Timothy Beukelman⁹ and for the CARRA Registry Investigators, ¹Pediatrics, Seattle Children's Hospital, Seattle, WA, ²Hackensack University Medical Center, Hackensack, NJ, ³Pediatrics, Duke Medical Center, Durham, NC, ⁴Intelligent Health Labs, Children's Hospital Boston, Boston, MA, ⁵Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁷Childhood Arthritis and Research Rheumatology Alliance (CARRA), Durham, NC, ⁸Childhood Arthritis and Rheumatology Research Alliance (CARRA), Durham, NC, ⁹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry is a multicenter, prospective observational study collecting data from children with rheumatic diseases in order…
Abstract Number: 2417 • 2016 ACR/ARHP Annual Meeting
High Dimensional Interrogation of the T Cell Immunome in Polyarticular Juvenile Idiopathic Arthritis Patients
Jing Yao Leong¹, Justin Tiong², Joo Guan Yeo^2,3, Liyun Lai¹, Phyllis Chen³, Loshinidevi D/O Thana Bathi³, Thaschawee Arkachaisri², Daniel J Lovell⁴ and Salvatore Albani^1,5, ¹SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, ²Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ³Singhealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, ⁴PRCSG Cincinnati Children's Hospital Medical Center, Cinncinnati, OH, ⁵Duke-National University of Singapore Medical School, Singapore, Singapore
Background/Purpose: Clinical management of polyarticular JIA with anti-TNF-alpha has been met with moderate success, with up to 50% of patients demonstrating clinically meaningful efficacy. Concerns…
Abstract Number: 406 • 2016 ACR/ARHP Annual Meeting
Adults with Juvenile Idiopathic Arthritis Are Not Adults with Rheumatoid Arthritis
Rayford R. June¹, Danielle Feger², Nicholas Longson³, Barbara E. Ostrov^4,5 and Nancy J. Olsen⁶, ¹Rheumatology, Penn State Hershey Medical Center, Hershey, PA, ²Medicine/Rheumatology, Penn State College of Medicine, Hershey, PA, ³Johns Hopkins University, Baltimore, MD, ⁴Pediatrics, Penn State Hershey Medical Center, Hershey, PA, ⁵Pediatrics, Penn State Hershey Children's Hospital, Hershey, PA, ⁶Medicine/Rheumatology, Penn State Hershey Medical Center, Hershey, PA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) persisting into adulthood is associated with articular damage, increased disability and mortality. Approximately 100,000 polyarticular JIA patients will enter adult…
Abstract Number: 3114 • 2016 ACR/ARHP Annual Meeting
Cardiorespiratory Fitness in Children with Juvenile Idiopathic Arthritis Treated in the Biological Era Is Comparable with Controls- a Cross-Sectional Study
Kristine Risum¹, Elisabeth Edvardsen^2,3, Anne Marit Selvaag⁴, Oyvind Molberg⁴, Hanne Dagfinrud⁵ and Helga Sanner^4,6, ¹Department of Rehabilitation, Division of Orthopeadic Surgery, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ²Department of Sports Medicine, Norwegian School of Sport Sciences, Oslo, Norway, Oslo, Norway, ³Department of Pulmonary Medicine, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁵Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ⁶Norwegian National Advisory Unit on Rheumatic Diseases in Children and Adolescents, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Cardiorespiratory Fitness in Children with Juvenile Idiopathic Arthritis Treated in the Biological Era is Comparable with Controls- a Cross-Sectional Study Background/Purpose: Reduced cardiorespiratory fitness (CRF)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].